James E. Schiller

Statistics

Publications

Citations

261

H-Index

Active since

2011

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Tennessee Health Science Center

James E. Schiller is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, clinical pharmacology, and pharmacy.

Publications per year

2011–2018

Publications

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Stergios J. Moschos, Ryan J. Sullivan, Wen-Jen Hwu et al. · JCI Insight · 2018 · 147 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

Teddy Kosoglou, Walter K. Kraft, Bharath Kumar et al. · European Journal of Clinical Pharmacology · 2012 · 29 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

Paul Statkevich, Teddy Kosoglou, Richard A. Preston et al. · European Journal of Clinical Pharmacology · 2012 · 27 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

Teddy Kosoglou, Larisa Reyderman, Claudia Kasserra et al. · European Journal of Clinical Pharmacology · 2011 · 25 citations

Medicine, Pharmacokinetics, Pharmacology +10

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single‐ and Multiple‐Dose Pharmacokinetics of Vorapaxar

Teddy Kosoglou, Paul Statkevich, Bharath Kumar et al. · The Journal of Clinical Pharmacology · 2013 · 21 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

1–5 of 6